News | News By Subject | News by Disease News By Date | Search News

Cytomegalovirus (CMV) News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Merck & Co. (MRK)'s CMV Drug Passes Clinical Endpoints in Phase III Trial     10/19/2016
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
EXCLUSIVE: Chimerix (CMRX) Says 2015 Will Be "Pivotal" Year, In Talks With Regulators to Use Antiviral After Transplants     2/19/2015
Pfizer (PFE) Takes Controlling Interest In Startup; Grabs Access of Preclinical CMV Candidate     1/5/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
ViroPharma Incorporated (VPHM) Announces Positive Phase 2 Results Demonstrating That Maribavir Significantly Reduces CMV Reactivation     3/30/2006
FDA Grants Vical Incorporated (VICL) Orphan-Drug Designation For CMV DNA Vaccine     6/14/2005
Kemin Pharma Identifies Unique New Molecule Effective Against Human Cytomegalovirus, An Important Breakthrough For AIDS Patients, Chemotherapy Patients And Other Immunodeficient Patients     11/11/2003

News from Around the Web

Press Releases
FDA Green Lights QIAGEN N.V. (QGEN)'s CMV Testing on Automated QIAsymphony Platform     6/6/2017
Adaptive Biotech Publishes Ground-Breaking Proof-Of-Principle Experiment In Nature Genetics     4/5/2017
Chimerix (CMRX) Announces Preliminary Data From Ongoing Phase I Dose Escalation Study Of Intravenous Brincidofovir In Healthy Subjects     1/6/2017
Fate Therapeutics (FATE) Announces FDA Clearance Of Investigational New Drug Application For Protmune For Prevention Of Acute Gvhd And CMV Infection     1/27/2016
VBI Vaccines To Present Update And New Data Supporting Its RSV And CMV Vaccine Programs At The World Vaccine Congress Europe     11/6/2015
Chimerix (CMRX) Provides Clinical Development Update For Brincidofovir     9/9/2015
New Company To Develop Vaccines, Discovered By City of Hope Researchers, To Protect Against CMV Infections In Cancer Patients     5/4/2015
Vical Incorporated (VICL) Announces Presentation Of Preclinical Data For Congenital CMV DNA Vaccine At International Conference     4/21/2015
VBI Vaccines Announces New Data Supporting The Manufacture Of Its Prophylactic CMV Vaccine Candidate     4/9/2015
New Data Supporting VBI's Prophylactic Cytomegalovirus (CMV) Vaccine Candidate (VBI-1501A) Presented At The 54th ICAAC Conference In Washington, D.C.     9/16/2014
Data On Chimerix, Inc. (CMRX)'s Brincidofovir Suggests Favorable Resistance Profile In Adenovirus And Cytomegalovirus (CMV)     9/9/2014
Theraclone Sciences, Inc. Presents Positive Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection at ICAAC 2013     9/11/2013
ViroPharma Incorporated (VPHM) Provides Update From Ongoing Phase 2 Studies of Maribavir for Treatment of Cytomegalovirus (CMV) Infections     6/28/2013
Vical Incorporated (VICL) and Astellas Pharma Inc. (YPH.BE) Announce Initiation of Phase 3 Trial of ASP0113 Cytomegalovirus Vaccine     6/25/2013
Theraclone Sciences, Inc. Announces Initiation of a Phase 1 Clinical Trial of TCN-202, an Antibody in Development for the Treatment of Human Cytomegalovirus Infection     6/14/2012